Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

Post author:
Post published:June 22, 2024
Post category:uncategorized

Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA).

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

The impact of implementing a high sensitivity assay for cardiac troponin I on long term outcomes in patients with suspected acute coronary syndrome

Premature surgical menopause can lead to increased risk of muscle disorders

Long-term hormone therapy proves valuable for older women

Helpful Links

Subscribe To Us